Suppliers and packagers for generic pharmaceutical drug: ferric oxyhydroxide

ferric oxyhydroxide

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109	NDA	Fresenius Medical Care Renal Therapies Group, LLC	49230-645-51	1 BOTTLE in 1 CARTON (49230-645-51) / 90 TABLET, CHEWABLE in 1 BOTTLE	2013-11-27

Ferric Oxyhydroxide Pharmaceutical Suppliers: Market Landscape and Strategic Considerations

Last updated: February 19, 2026

Ferric oxyhydroxide (FOH) is a key active pharmaceutical ingredient (API) primarily utilized as an iron-binding phosphate binder in the treatment of hyperphosphatemia, particularly in patients with chronic kidney disease (CKD). The global market for FOH suppliers is characterized by a limited number of specialized manufacturers, stringent regulatory requirements, and a growing demand driven by the aging global population and the increasing prevalence of CKD. This analysis examines the current supplier landscape, key market dynamics, and strategic considerations for pharmaceutical companies.

Who are the Primary Suppliers of Ferric Oxyhydroxide for Pharmaceutical Use?

The production of pharmaceutical-grade ferric oxyhydroxide demands specialized manufacturing processes to ensure high purity, specific particle size distribution, and absence of contaminants. The supplier base is concentrated, with several key players dominating the market.

• West-Ward Pharmaceuticals: A subsidiary of Hikma Pharmaceuticals, West-Ward is a significant supplier of generic pharmaceutical products, including those containing ferric oxyhydroxide. They operate under strict Good Manufacturing Practices (GMP) and hold a notable market share in iron-based phosphate binders.
• Covis Pharma: This company offers Velphoro®, a branded ferric oxyhydroxide chewable tablet. While a branded product, Covis Pharma is also involved in the supply chain for the API itself or has established agreements with specific API manufacturers.
• Sanochem Pharmaceuticals: This Polish pharmaceutical company has been noted for its involvement in the production and supply of APIs, including those for iron-based therapies. Their manufacturing capabilities are geared towards meeting international pharmaceutical standards.
• Chephasaar Pharmaceuticals: Chephasaar is an India-based pharmaceutical company that develops and manufactures APIs and finished dosage forms. They are known to produce intermediates and APIs for various therapeutic areas, including iron deficiencies.
• Specific Contract Manufacturing Organizations (CMOs) and API Producers: Beyond direct pharmaceutical companies, a segment of specialized chemical manufacturers and CMOs produce FOH under contract for larger pharmaceutical firms. These entities often possess expertise in metal oxide synthesis and purification. Identifying these entities requires deeper supply chain intelligence due to confidentiality agreements.

What are the Key Regulatory and Quality Requirements for Ferric Oxyhydroxide Suppliers?

Suppliers of pharmaceutical-grade ferric oxyhydroxide must adhere to rigorous quality and regulatory standards to ensure patient safety and product efficacy. These requirements are overseen by global health authorities.

• Good Manufacturing Practices (GMP): Compliance with current GMP regulations (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others is mandatory. This includes controls over manufacturing processes, facility maintenance, personnel training, and quality control testing.
• Drug Master Files (DMFs): Suppliers typically maintain DMFs submitted to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facility, quality control, and stability of the API. Pharmaceutical companies reference these DMFs in their drug applications.
• Purity and Impurity Profiles: Stringent limits are set for impurities, including heavy metals, residual solvents, and related substances. The physical characteristics, such as particle size distribution and surface area, are critical for formulation and bioavailability.
• Pharmacopoeial Standards: FOH must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). These standards define acceptable limits for identity, purity, and strength.
• Elemental Impurities: As a metal oxide, FOH is subject to strict controls for elemental impurities as outlined in ICH Q3D guidelines. This includes testing for potentially toxic elements.
• Supply Chain Integrity: Robust supply chain management is required to prevent counterfeiting and ensure the traceability and authenticity of the API from raw material to finished product.

What are the Market Dynamics and Growth Drivers for Ferric Oxyhydroxide?

The demand for ferric oxyhydroxide is influenced by several interconnected factors, predominantly related to kidney disease progression and patient demographics.

• Prevalence of Chronic Kidney Disease (CKD): CKD is a global health issue, with increasing rates of diagnosis and progression. Hyperphosphatemia is a common complication of CKD, necessitating effective phosphate binders like FOH.
  • Global CKD Cases: Estimated to affect 10% of the world's population (approximately 850 million people) [1].
  • Prevalence in Dialysis Patients: Hyperphosphatemia is almost universal in patients on hemodialysis.
• Aging Global Population: Older individuals are more susceptible to CKD and its associated complications, leading to a greater demand for treatments.
  • Global Elderly Population Growth: The proportion of the global population aged 65 and over is projected to rise from 9.3% in 2019 to 15.3% by 2050 [2].
• Development of Novel Formulations and Delivery Systems: Ongoing research into more convenient and palatable formulations of FOH can expand market access and patient compliance.
• Shift from Traditional Phosphate Binders: Ferric oxyhydroxide offers advantages over some older phosphate binders, such as calcium-based binders (which can contribute to hypercalcemia and vascular calcification) and sevelamer (which can cause gastrointestinal side effects). FOH generally has a favorable gastrointestinal tolerability profile.
• Generic Competition: As patents expire for branded FOH products, the entry of generic alternatives can increase accessibility and volume demand, while also intensifying price competition among suppliers.
• Geographic Market Growth: Developing economies with increasing healthcare access and rising rates of lifestyle-related diseases (like diabetes and hypertension, key drivers of CKD) represent significant growth opportunities.

What are the Challenges Faced by Ferric Oxyhydroxide Suppliers?

Suppliers of ferric oxyhydroxide navigate a landscape marked by stringent regulatory hurdles, intense competition, and complex manufacturing demands.

• High Barriers to Entry: The capital investment required for GMP-compliant manufacturing facilities, extensive regulatory documentation, and rigorous quality control systems creates significant barriers for new entrants.
• Supply Chain Complexity and Raw Material Sourcing: Ensuring a consistent and high-quality supply of precursor materials for FOH synthesis is crucial. Disruptions in raw material availability or quality can impact production.
• Price Pressures: The market for phosphate binders is competitive, particularly with the advent of generics. Suppliers must balance the need for high-quality production with competitive pricing.
• Regulatory Scrutiny and Compliance Costs: Maintaining continuous compliance with evolving GMP standards and other regulatory requirements is a significant ongoing cost for suppliers. Any lapse can result in product recalls, fines, and reputational damage.
• Intellectual Property Landscape: While the API itself might be off-patent, there can be patents related to specific manufacturing processes, particle morphologies, or formulations that suppliers must navigate.
• Competition from Alternative Therapies: While FOH is effective, ongoing research into novel treatments for hyperphosphatemia, including new classes of binders or non-binder therapies, could introduce future competitive pressures.

What are the Strategic Considerations for Pharmaceutical Companies Sourcing Ferric Oxyhydroxide?

Pharmaceutical companies relying on ferric oxyhydroxide for their products must adopt a strategic approach to supplier management to ensure reliable supply, quality, and cost-effectiveness.

• Dual Sourcing and Supplier Diversification: To mitigate supply chain risks, securing supply from at least two qualified manufacturers is highly recommended. This reduces reliance on a single source and provides leverage in negotiations.
• Rigorous Supplier Qualification and Auditing: A comprehensive qualification process is essential. This includes reviewing regulatory compliance records, conducting on-site GMP audits, and assessing the supplier’s financial stability and capacity.
• Long-Term Supply Agreements: Negotiating long-term supply agreements can secure pricing stability, ensure dedicated production capacity, and foster a collaborative relationship with key suppliers. These agreements should clearly define quality specifications, delivery schedules, and change control procedures.
• Supply Chain Transparency and Traceability: Companies should demand complete transparency regarding the origin of raw materials and the manufacturing process. Implementing robust traceability systems from raw material to finished API is critical for quality assurance and regulatory compliance.
• Quality by Design (QbD) Principles: Working with suppliers who embrace QbD principles can lead to more robust and consistent API quality. This involves understanding critical process parameters and critical quality attributes that affect the final API.
• Monitoring Regulatory and Market Trends: Staying abreast of regulatory changes, emerging competition, and new therapeutic developments in the phosphate binder market is crucial for informed sourcing decisions and strategic planning.
• Cost-Benefit Analysis of Branded vs. Generic APIs: Pharmaceutical companies must weigh the benefits of sourcing from a well-established branded API supplier (often with a long track record and comprehensive regulatory support) against the cost advantages and broader availability of generics.

Key Takeaways

The ferric oxyhydroxide market is characterized by a concentrated supplier base driven by the growing prevalence of chronic kidney disease and hyperphosphatemia. Regulatory compliance, particularly GMP standards and pharmacopoeial specifications, is paramount. Pharmaceutical companies must prioritize supply chain resilience through dual sourcing, rigorous supplier qualification, and transparent relationships. Strategic sourcing decisions should balance quality, reliability, and cost in a competitive landscape.

FAQs

1. What are the primary therapeutic uses of ferric oxyhydroxide in pharmaceuticals? Ferric oxyhydroxide is primarily used as an iron-binding phosphate binder to treat hyperphosphatemia, a common complication in patients with chronic kidney disease.

2. Which regulatory bodies have the most significant impact on ferric oxyhydroxide suppliers? The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory authorities in other major markets (e.g., PMDA in Japan) are the primary regulatory bodies. Compliance with ICH guidelines is also globally relevant.

3. How does particle size distribution affect the performance of ferric oxyhydroxide? Particle size distribution and surface area are critical physicochemical properties that influence the iron-binding capacity and dissolution rate of ferric oxyhydroxide, directly impacting its efficacy as a phosphate binder.

4. What are the main risks associated with sourcing ferric oxyhydroxide from a single supplier? Sourcing from a single supplier increases the risk of supply chain disruption due to manufacturing issues, regulatory actions, natural disasters, or geopolitical events, potentially leading to product shortages and impacting patient access.

5. Are there emerging alternative therapies that could impact the demand for ferric oxyhydroxide? Yes, research is ongoing into novel phosphate binders with potentially improved efficacy or tolerability profiles, as well as non-binder therapies. These could, in the long term, affect the market share of existing treatments like ferric oxyhydroxide.

Citations

[1] Institute for Health Metrics and Evaluation. (n.d.). Global Burden of Disease Collaborative Network. Retrieved from http://ghdx.healthdata.org/gbd-results-tool

[2] United Nations, Department of Economic and Social Affairs, Population Division. (2019). World Population Prospects 2019: Highlights. https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf